When the Evidence Finally Gets Read
The most significant recent development in this story is the systematic reversal now underway in European countries that were among the earliest and most aggressive adopters of affirmation-only clinical models for gender dysphoric youth.
The Cass Review
In April 2024, the National Health Service of England published the final 388-page report of the Cass Review — a four-year independent review chaired by Dr. Hilary Cass, former president of the Royal College of Paediatrics and Child Health. Commissioned to evaluate the evidence base for pediatric gender medicine, the Review commissioned nine studies, eight of which were systematic reviews of the existing literature. The findings were significant on multiple levels:
Systematic reviews of gender-affirming medical interventions consistently revealed poor or very low quality evidence across the literature.
There is no evidence that puberty blockers reduce suicide risk — contrary to the claim routinely used to justify their use in clinical settings.
The data shows that the vast majority of adolescents placed on puberty blockers proceed directly to cross-sex hormones, contradicting the claim that blockers simply “buy time” for reflection.
When UK clinicians attempted to replicate Dutch research showing mental health improvements following gender-affirming intervention, they found no improvements. In the words of Dr. Cass herself: “some young people got worse.”
The Review explicitly named diagnostic overshadowing as a systemic failure — the clinical focus on gender-related treatments had overshadowed the possibility that evidence-based treatments for depression, anxiety, trauma, and autism might be more effective.
The Cass Review is a government-commissioned, independently conducted, four-year review based on eight systematic reviews of the existing literature. It is published, publicly available, and its findings have been accepted by NHS England.
The Dutch Protocol Misapplication
The Cass Review also identified a critical finding about how the evidence base for gender-affirming care had been constructed. The original Dutch protocol — pioneered at the VU University Medical Center in Amsterdam — operated under strict eligibility criteria: childhood-onset gender dysphoria only, no significant psychiatric comorbidities, a stable social environment, and careful psychological assessment before any medical intervention.
This protocol was then exported to clinics worldwide — but without those criteria. The new cohort of patients flooding Western gender clinics was precisely the population the Dutch researchers had excluded: adolescent females with no childhood history, extensive psychiatric comorbidities, social media influence, and peer-group clustering. The treatment was adopted globally while the safeguards that made the original research defensible were abandoned.
The Self-Referential Guideline Cycle
This circularity deserves explicit attention because it is the mechanism by which “feel good science” maintains itself once established. The cycle operates as follows: WPATH publishes clinical guidelines. The Endocrine Society develops its own guidelines and cites WPATH as a primary authority. National medical associations in turn cite both WPATH and the Endocrine Society. Clinicians cite the national guidelines as justification for their practice. Researchers cite the clinical practice as evidence of consensus. And WPATH cites the “consensus” in its next revision.
At no point in this cycle did anyone go back to the primary evidence and conduct an independent systematic review asking the foundational question: does this treatment actually produce the outcomes it claims? The Cass Review was the first major review to break that cycle — and the intensity of the reaction to it illustrates how violently a self-referential system responds when someone actually checks the evidence.
The WPATH Files
Documents later unsealed in US legal proceedings revealed that WPATH — the organization whose guidelines had been adopted as the international standard of care — required its commissioned systematic reviewers to have findings approved by WPATH leadership before publication. This process resulted in only one of the commissioned reviews being published. The systematic reviews that WPATH itself had commissioned — presumably to establish the evidence base for its own guidelines — were suppressed when the findings did not support the predetermined conclusions. This is not an allegation; it is documented in court filings and has been reported in multiple media outlets.
The WPATH documents were unsealed in US legal proceedings and are part of the public court record.
Hearing the Other Side
The Proverbs 18:17 standard requires that we present the strongest case against our own argument. The Cass Review has not gone uncontested.
A white paper published through Yale Law School in July 2024 critiqued the Review’s methodology and argued that gender-affirming care for youth is well-supported by evidence. The Canadian Paediatric Society described “significant limitations, biases, and inaccuracies” in the Review. A collaboration of Germany, Austria, and Switzerland produced clinical guidelines that criticized the Cass Review’s methodology and conclusions. A peer-reviewed critical evaluation published in BMC Medical Research Methodology in May 2025 applied the ROBIS tool to the Review’s systematic reviews and identified methodological concerns. The British Medical Association voted to publicly critique the Cass Review and called for a pause on implementing its recommendations.
These critiques deserve acknowledgment. However, the critiques have themselves been critiqued — and the Cass Review has survived the examination. A peer-reviewed fact-check published in the Journal of Sex & Marital Therapy reviewed the Yale critique and three other published criticisms, finding that each contained claims that necessitate correction or clarification. An analysis published in BMJ’s Archives of Disease in Childhood concluded that the Yale critique was not a genuine scientific effort but a politicized attempt to influence outcomes of ongoing U.S. litigation.
The pattern is itself illustrative of this paper’s thesis: a systematic evidence review that found poor quality evidence for a politically favored intervention was attacked primarily by those with institutional commitments to that intervention. The critiques did not produce new evidence that the Cass Review’s systematic reviews had missed. They challenged the review’s standards — arguing, in effect, that the evidence bar for gender-affirming care should be lower than for other pediatric interventions.
The Cass Review’s findings are Tier 1 verified. The debate over its implications — whether low-quality evidence justifies restricting access to care, or whether the precautionary principle demands higher evidence standards for irreversible interventions in minors — is a genuine interpretive disagreement between credentialed experts operating from different clinical frameworks.
The Broader European Response and the American Reckoning
England was not alone. The European Society for Child and Adolescent Psychiatry, drawing on systematic reviews from Sweden, Finland, Germany, and the UK, called for healthcare providers not to promote experimental and unnecessarily invasive treatments with unproven psychosocial effects, and insisted on the importance of respect for all kinds of different views and attitudes in professional debate.
Multiple countries that had pioneered gender-affirming pediatric care — Sweden, Finland, Denmark, the UK — have now reversed course, implementing restrictions on puberty blockers and redirecting clinical resources toward psychological support and treatment of comorbid psychiatric conditions.
In the United States, the reckoning is beginning. In February 2026, the American Society of Plastic Surgeons became the first major U.S. medical association to change its guidance on gender-affirming surgery for minors, recommending against chest, genital, and facial surgeries until age 19, citing insufficient evidence.
The pattern is exactly what the Cass Review describes and what the detransitioner research confirms: a generation of clinically vulnerable adolescents received affirmation when they needed differential diagnosis. The reckoning, when it came, was not driven by ideology but by evidence that could no longer be ignored.